Patents by Inventor Eric Furfine

Eric Furfine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20230374108
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Application
    Filed: June 29, 2023
    Publication date: November 23, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric FURFINE, Daniel DIX, Kenneth GRAHAM, Kelly FRYE
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 11732024
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Grant
    Filed: June 15, 2021
    Date of Patent: August 22, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20210340220
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Application
    Filed: June 15, 2021
    Publication date: November 4, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric FURFINE, Daniel DIX, Kenneth GRAHAM, Kelly FRYE
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 11084865
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: August 10, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 11066458
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: July 20, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • Serum albumin binding molecules
    Patent number: 10934572
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: March 2, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael L. Gosselin, David Fabrizio, Joanna F. Swain, Tracy Mitchell, Ray Camphausen, Sharon T. Cload, Eric Furfine, Paul E. Morin, Ranjan Mukherjee, Simeon I. Taylor
  • MULTIVALENT FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS
    Publication number: 20210017252
    Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: August 6, 2020
    Publication date: January 21, 2021
    Inventors: Ray CAMPHAUSEN, Eric FURFINE, Irvith M. CARVAJAL, H. Nicholas MARSH, Marco GOTTARDIS, Joan CARBONI, Ricardo ATTAR
  • Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins
    Patent number: 10774130
    Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: September 15, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, Eric Furfine, Irvith M. Carvajal, H. Nicholas Marsh, Marco Gottardis, Joan Carboni, Ricardo Attar
  • VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20200131246
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Application
    Filed: January 10, 2020
    Publication date: April 30, 2020
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric FURFINE, Daniel DIX, Kenneth GRAHAM, Kelly FRYE
  • VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20200017572
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Application
    Filed: September 25, 2019
    Publication date: January 16, 2020
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric FURFINE, Daniel DIX, Kenneth GRAHAM, Kelly FRYE
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 10464992
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO: 4.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: November 5, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 10400025
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: September 3, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • SERUM ALBUMIN BINDING MOLECULES
    Publication number: 20190203248
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: January 10, 2019
    Publication date: July 4, 2019
    Inventors: Michael L. GOSSELIN, David FABRIZIO, Joanna F. SWAIN, Tracy MITCHELL, Ray CAMPHAUSEN, Sharon T. CLOAD, Eric FURFINE, Paul E. MORIN, Ranjan MUKHERJEE, Simeon I. TAYLOR
  • Serum albumin binding molecules
    Patent number: 10221438
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: March 5, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael L. Gosselin, David Fabrizio, Joanna F. Swain, Tracy Mitchell, Ray Camphausen, Sharon T. Cload, Eric Furfine, Paul E. Morin, Ranjan Mukherjee, Simeon I. Taylor
  • VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20190031735
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO: 4.
    Type: Application
    Filed: October 12, 2018
    Publication date: January 31, 2019
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric FURFINE, Daniel DIX, Kenneth GRAHAM, Kelly FRYE
  • MULTIVALENT FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS
    Publication number: 20180265572
    Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: January 10, 2018
    Publication date: September 20, 2018
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray CAMPHAUSEN, Eric FURFINE, Irvith M. CARVAJAL, H. Nicholas MARSH, Marco GOTTARDIS, Joan CARBONI, Ricardo ATTAR
  • VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20180155408
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Application
    Filed: January 24, 2018
    Publication date: June 7, 2018
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric FURFINE, Daniel DIX, Kenneth GRAHAM, Kelly FRYE
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 9914763
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: March 13, 2018
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • Multivalent fibronectin based scaffold domain proteins
    Patent number: 9902762
    Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: February 27, 2018
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, Eric Furfine, Irvith M. Carvajal, H. Nicholas Marsh, Marco Gottardis, Joan Carboni, Ricardo Attar
  • SERUM ALBUMIN BINDING MOLECULES
    Publication number: 20170145464
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: November 29, 2016
    Publication date: May 25, 2017
    Inventors: Michael L. GOSSELIN, David FABRIZIO, Joanna F. SWAIN, Tracy MITCHELL, Ray CAMPHAUSEN, Sharon T. CLOAD, Eric FURFINE, Paul E. MORIN, Ranjan MUKHERJEE, Simeon I. TAYLOR